Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?

Published:2019-03 Issue:2 Volume:5 Page:125-133
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Shevach Jeffrey,Sydes Matthew R.,Hussain Maha^ORCID

Publisher

Elsevier BV

Subject

Urology

Reference59 articles.

1. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941;Huggins;J Urol,2002

2. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

3. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

4. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial;Quinn;Lancet Oncol,2013

5. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?;Grossmann;Clin Endocrinol,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men;Journal of Urology;2021-10

2. Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial;Cancer Medicine;2021-05

3. Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn’t Gold;European Urology;2020-11

4. Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer;PLOS ONE;2020-03-24

5. Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer;European Urology Focus;2019-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3